• Explore /
  • Poster
  • / Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.

Abstract Poster

Authors

Vivek Subbiah

Vivek Subbiah

The University of Texas MD Anderson Cancer Center, Houston, TX

Vivek Subbiah , Mark M. Awad , Adil Daud , Martin Gutierrez , Jessica Dreger McDermott , Sai-Hong Ignatius Ou , Tomoko Hirohashi , Kim Ingram , Colleen Oliver , Derek Smith , Lance Wollenberg , James L. Abbruzzese

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04458259

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2671)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2671

Abstract #

TPS2671

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Tomoko Hirohashi

First Author: Jessica Dreger McDermott

First Author: Funda Meric-Bernstam

First Author: Nong Xu